Abstract
The use of targeted therapies (TT) and checkpoint inhibitors (IT) in patients with melanoma significantly prolonged survival, especially in the group of patients with BRAF-mutated melanoma. The aim of this study was to evaluate real-life outcomes of advanced melanoma second line therapy in TT-IT and IT-TT sequence with BRAFi/MEKi combination or anti-PD1 agent.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
